Skip to main content
. 2023 Mar 10;11(3):842. doi: 10.3390/biomedicines11030842

Figure 1.

Figure 1

Figure 1

Changes in vascular endothelial growth factor receptor 2 (VEGF-R2) (a), vascular endothelial growth factor receptor 3 (VEGF-R3) (b), and vascular cell adhesion molecule-1 (VCAM-1) (c) levels during somatostatin analogue (SSAs) treatment in patients with neuroendocrine tumors.